J Investig Allergol Clin Immunol. 2014;24(1):35-9.
Allergen immunotherapy (AIT) has proven to be effective. However, no biomarkers capable of predicting the clinical response to AIT have been detected. The aim of the present study was to determine a cutoff value for serum specific IgE that could be associated with effective AIT.
We evaluated 174 allergic patients (83 males) with ages ranging between 6 and 77 years. All patients were monsensitized and received sublingual immunotherapy (SLIT) for at least 3 years with a single allergen extract. Symptom severity was assessed using the visual analog scale (VAS). Drug use was also evaluated. A responder was defined as a patient whose VAS score fell by at least 30% over baseline.
The response to SLIT was considered effective in 145 patients (83.3%). The use of allergen-specific IgE levels > 9.74 kU(A)/L as a biomarker of effective SLIT yielded a sensitivity value of 96.4%, specificity of 100%, and an area under the receiver operator characteristic curve of 0.987.
Assessment of serum specific-IgE before AIT could be a useful biomarker for predicting response to AIT.
过敏原免疫疗法（AIT）已被证明是有效的。然而，尚未发现能够预测 AIT 临床反应的生物标志物。本研究的目的是确定与有效 AIT 相关的血清特异性 IgE 的截断值。
我们评估了 174 名过敏患者（83 名男性），年龄在 6 至 77 岁之间。所有患者均为单敏，并接受舌下免疫疗法（SLIT）治疗，至少 3 年，使用单一过敏原提取物。使用视觉模拟量表（VAS）评估症状严重程度。还评估了药物使用情况。将 VAS 评分至少下降 30%基线的患者定义为应答者。
145 名患者（83.3%）对 SLIT 的反应被认为是有效的。将过敏原特异性 IgE 水平>9.74 kU(A)/L 用作有效 SLIT 的生物标志物，其灵敏度为 96.4%，特异性为 100%，受试者工作特征曲线下面积为 0.987。
AIT 前评估血清特异性 IgE 可能是预测 AIT 反应的有用生物标志物。
